💊Drug Safety Associate Role for Freshers in Hyderabad
📌 Position Details
Role: Drug Safety Associate (ICSR Literature)
Company: Leading Global Lifescience Company
Experience: Freshers (0–1 Year)
Location: Hyderabad
Salary: ₹2.8 LPA
Education: B.Pharm, M.Pharm, Pharm.D, M.Sc, B.Sc, Life Sciences
Application Mode: ✅ Online
Job Type: ✅ Verified Job
🏢 About the Company
A global pharmaceutical leader, this company is focused on patient safety, pharmacovigilance, and drug efficacy. Based in Hyderabad, it partners with global clients to provide regulatory-compliant solutions in drug safety, clinical research, and literature-based case processing.
📝 Job Description: Drug Safety Associate (ICSR Literature)
Start your career in pharmacovigilance with hands-on experience in literature-based ICSR reporting and drug safety processes.
🧾 Key Responsibilities:
-
Conduct literature screening to identify adverse drug reactions (ADRs)
-
Review scientific journals and databases for safety signals
-
Enter and process cases in pharmacovigilance systems
-
Ensure global regulatory compliance (ICH-GCP, FDA, EMA)
-
Collaborate with international drug safety teams
-
Maintain high-quality documentation and case narratives
✅ Eligibility Criteria
-
Education: B.Pharm, M.Pharm, Pharm.D, M.Sc, B.Sc, Life Sciences
-
Experience: Freshers welcome (0–1 year)
-
Gender Preference: Male candidates only (due to shift/work conditions)
-
Skills Needed:
-
Basic understanding of PV & ICSR
-
Strong literature review and analytical thinking
-
MS Office proficiency
-
Good communication & attention to detail
-
🎁 Benefits & Perks
✨ Competitive salary with performance bonuses
✨ Health insurance & wellness support
✨ Career path in pharmacovigilance
✨ Work in a reputed pharma MNC
✨ Flexible, growth-focused work environment
For more Jobs...
Click Here
📅 Apply Now – Limited Openings
🔐 Verified by Medical Jobs India – hitechplus.in
✔ Real-Time Alerts | ✔ Verified Jobs | ✔ Trusted Employers | ✔ Career Growth
📢 Join Our WhatsApp Channel!
Stay updated with latest job alerts & updates.
0 Comments